{"schema_version":"secwatch.filing_event.v1","accession":"0001683168-23-003122","form_type":"8-K","ticker":"PAYS","cik":"0001496443","company_name":"Paysign, Inc.","filed_at":"2023-05-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.057915+00:00","generated_at":"2026-06-15T06:13:58.606639+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Paysign Q1 rev +23% to $10.1M, net loss narrows; Q2 guidance calls for continued growth","bullets":["Q1 2023 revenues $10.1M (+23% YoY); net loss $0.2M improved from $0.3M loss a year ago.","Adjusted EBITDA $0.7M (down 22% YoY); guided Q2 rev growth 15-20%, Adj. EBITDA growth 5-10%.","Added 10 plasma centers (total 439); launched 7 pharma copay programs (total 26); gross spend +31%.","Unrestricted cash $6.4M (down $3.3M from Dec 2022) due to AR build, capex, and $0.7M stock buyback.","Gross margin fell to 49.8% from 60.8% on higher third-party costs and mix shift toward lower-margin plasma."],"urls":{"canonical":"https://secwatch.observer/filing/0001683168-23-003122","json":"https://secwatch.observer/filing/0001683168-23-003122.json","markdown":"https://secwatch.observer/filing/0001683168-23-003122.md","text":"https://secwatch.observer/filing/0001683168-23-003122.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1496443/000168316823003122/0001683168-23-003122-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1496443/000168316823003122/paysign_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T06:13:58.606639+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a68d0809a436618a3723d780f9171d86d38b7110","claim":"Paysign, Inc. reported first quarter 2023 results: revenue $10.1 million, net income ($0.2) million, EPS ($0.00) per diluted share.","evidence_excerpt":"First quarter total revenues of $10.1 million, up 23% from first quarter 2022 · First quarter net loss of ($0.2) million, or diluted loss per share of ($0.00)","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1496443/000168316823003122/0001683168-23-003122-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter 2023"},{"label":"Revenue","value":"$10.1 million"},{"label":"Net income","value":"($0.2) million"},{"label":"EPS","value":"($0.00) per diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}